HeartBeam to Participate in the H.C. Wainwright BIOCONNECT Conference
December 29 2021 - 8:31AM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology to bring new capabilities to cardiovascular disease,
announced today it will participate in the H.C. Wainwright
BIOCONNECT Conference being held virtually January 10 – 13,
2022.
HeartBeam Chief Executive Officer and Founder Branislav Vajdic,
PhD, Chief Financial Officer Rick Brounstein, and Chief Business
Officer Jon Hunt, PhD, will conduct 30-minute video one-on-one
meetings during the conference.
H.C. Wainwright BIOCONNECT Conference Date: January 10 –
13, 2022 Presentation Time: Available on-demand January 10, 2022 at
7:00 am ET (4:00 am Pacific time) Webcast:
https://journey.ct.events/view/b4bf55c1-dcc2-4132-b734-067c483ca52f
Format: Virtual 1x1’s and Virtual Presentations Speaker: Branislav
Vajdic, PhD, Chief Executive Officer and Founder Conference
Website: Click here
For more information on the H.C. Wainwright BIOCONNECT
Conference or to schedule a one-on-one meeting with HeartBeam
management, please contact your conference representative or you
may also email your request to BEAT@mzgroup.us or call Chris Tyson
at (949) 491-8235.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high-risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card-sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
diseases. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer patients and
their physicians this value. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information, visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our recently filed Registration Statement on Form S-1, which can
be found on the SEC’s website at www.sec.gov. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211229005038/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024